These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 8565166)

  • 1. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study.
    Wever EF; Hauer RN; Schrijvers G; van Capelle FJ; Tijssen JG; Crijns HJ; Algra A; Ramanna H; Bakker PF; Robles de Medina EO
    Circulation; 1996 Feb; 93(3):489-96. PubMed ID: 8565166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors.
    Wever EF; Hauer RN; van Capelle FL; Tijssen JG; Crijns HJ; Algra A; Wiesfeld AC; Bakker PF; Robles de Medina EO
    Circulation; 1995 Apr; 91(8):2195-203. PubMed ID: 7697849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
    Owens DK; Sanders GD; Heidenreich PA; McDonald KM; Hlatky MA
    Am Heart J; 2002 Sep; 144(3):440-8. PubMed ID: 12228780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can implantable cardioverter-defibrillator therapy reduce healthcare costs?
    Hauer RN; Derksen R; Wever EF
    Am J Cardiol; 1996 Sep; 78(5A):134-9. PubMed ID: 8820850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy.
    Larsen G; Hallstrom A; McAnulty J; Pinski S; Olarte A; Sullivan S; Brodsky M; Powell J; Marchant C; Jennings C; Akiyama T;
    Circulation; 2002 Apr; 105(17):2049-57. PubMed ID: 11980684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of sudden cardiac arrest survivors and electrophysiologically guided antiarrhythmic therapy.
    Hennersdorf MG; Niebch V; Vester EG; Winter J; Perings C; Strauer BE
    Cardiology; 2003; 99(4):190-7. PubMed ID: 12845245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death.
    Spath MA; O'Brien BJ
    Pharmacoeconomics; 2002; 20(11):727-38. PubMed ID: 12201792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up.
    Schläpfer J; Rapp F; Kappenberger L; Fromer M
    J Am Coll Cardiol; 2002 Jun; 39(11):1813-9. PubMed ID: 12039497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.
    O'Brien BJ; Buxton MJ; Rushby JA
    Br Heart J; 1992 Aug; 68(2):241-5. PubMed ID: 1389748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.
    Raviele A; Bongiorni MG; Brignole M; Cappato R; Capucci A; Gaita F; Mangiameli S; Montenero A; Pedretti R; Salerno J; Sermasi S
    Am J Cardiol; 1999 Mar; 83(5B):104D-111D. PubMed ID: 10089851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
    Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
    Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.